Evidence map›Paper›PMID 31088376›Full record

ArticleBMC infectious diseases2019

"It depends how one understands it:" a qualitative study on differential uptake of oral cholera vaccine in three compounds in Lusaka, Zambia.

Leonard W Heyerdahl, Miguel Pugliese-Garcia, Sharon Nkwemu, Taniya Tembo, Chanda Mwamba, Rachel Demolis, Roma Chilengi, Bradford D Gessner, Elise Guillermet, Anjali Sharma

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.7field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 26 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Knowledge, Attitude, and Practice in a Sample of the Lebanese Population Regarding Cholera.International journal of environmental research and public health · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Leonard W HeyerdahlAgence de Médecine Préventive, J 87, Deux Plateaux, Abidjan, Côte d'Ivoire. leonard.heyerdahl@ens-lyon.fr.ORCID http://orcid.org/0000-0001-5540-5388
Miguel Pugliese-GarciaCentre for Infectious Disease Research in Zambia (CIDRZ), Plot # 34620, P.O. Box 34681, 10101, Lusaka, Zambia.
Sharon NkwemuCentre for Infectious Disease Research in Zambia (CIDRZ), Plot # 34620, P.O. Box 34681, 10101, Lusaka, Zambia.
Taniya TemboCentre for Infectious Disease Research in Zambia (CIDRZ), Plot # 34620, P.O. Box 34681, 10101, Lusaka, Zambia.
Chanda MwambaCentre for Infectious Disease Research in Zambia (CIDRZ), Plot # 34620, P.O. Box 34681, 10101, Lusaka, Zambia.
Rachel DemolisAgence de Médecine Préventive, 13 chemin du Levant, 01210, Ferney-Voltaire, France.
Roma ChilengiCentre for Infectious Disease Research in Zambia (CIDRZ), Plot # 34620, P.O. Box 34681, 10101, Lusaka, Zambia.
Bradford D GessnerAgence de Médecine Préventive, 13 chemin du Levant, 01210, Ferney-Voltaire, France.
Elise GuillermetAgence de Médecine Préventive, 13 chemin du Levant, 01210, Ferney-Voltaire, France.
Anjali SharmaCentre for Infectious Disease Research in Zambia (CIDRZ), Plot # 34620, P.O. Box 34681, 10101, Lusaka, Zambia.
Centre for Infectious Disease Research in Zambia · ZMAgence de Médecine Préventive · FRÉcole Normale Supérieure de Lyon · FR

Funding

Bill & Melinda Gates Foundation OPP1106078
6 · The paper itself

Abstract

backgroundThe Zambian Ministry of Health implemented a reactive one-dose Oral Cholera Vaccine (OCV) campaign in April 2016 in three Lusaka compounds, followed by a pre-emptive second-round in December. Understanding uptake of this first-ever two-dose OCV campaign is critical to design effective OCV campaigns and for delivery of oral vaccines in the country and the region.

methodsWe conducted 12 Focus Group Discussions (FGDs) with men and women who self-reported taking no OCV doses and six with those self-reporting taking both doses. Simple descriptive analysis was conducted on socio-demographic and cholera-related data collected using a short questionnaire. We analyzed transcribed FGDs using the framework of dose, gender and geographic location.

resultsNo differences were found by gender and location. All participants thought cholera to be severe and the reactive OCV campaign as relevant if efficacious. Most reported not receiving information on OCV side-effects and duration of protection. Those who took both doses listed more risk factors (including 'wind') and felt personally susceptible to cholera and protected by OCV. Some described OCV side-effects, mostly diarrhoea, vomiting and dizziness, as the expulsion of causative agents. Those who did not take OCV felt protected by their good personal hygiene practices or, thought of themselves and OCV as powerless against the multiple causes of cholera including poor living conditions, water, wind, and curse. Most of those who did not take OCV feared side-effects reported by others. Some interpreted side-effects as 'western' malevolence. Though > 80% discussants reported not knowing duration of protection, some who did not vaccinate, suggested that rather than rely on OCV which could lose potency, collective action should be taken to change the physical and economic environment to prevent cholera.

conclusionsDue to incomplete information, individual decision-making was complex, rooted in theories of disease causation, perceived susceptibility, circulating narratives, colonial past, and observable outcomes of vaccination. To increase coverage, future OCV campaigns may benefit from better communication on eligibility and susceptibility, expected side effects, mechanism of action, and duration of protection. Governmental improvements in the physical and economic environment may increase confidence in OCV and other public health interventions among residents in Lusaka compounds.

Indexed as

Administration, OralAdolescentAdultAgedCholeraCholera VaccinesFemaleFocus GroupsHumansMaleMiddle AgedRisk FactorsSelf ReportSurveys and QuestionnairesVaccinationYoung AdultCholera VaccinesBeliefCholeraVaccine hesitancyZambia

Identifiers

PMID31088376
PMCPMC6518637
OpenAlexW2944842455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.